Drug major Sun Pharma in licensing pact with AstraZeneca UK for cancer products in China

Our Bureau Mumbai | Updated on November 06, 2019

File photo   -  File photo

Sun Pharma will be responsible for development, regulatory filings and manufacture of the products; AstraZeneca will promote and distribute these products in China

Drugmaker Sun Pharma has entered into a licensing agreement with AstraZeneca UK Ltd to introduce certain novel ready-to-use (RTU) infusion oncology products in China. Sun Pharma said the agreement will help bring cost-effective and quality drugs to patients in China. The agreement was announced today at the China International Import Expo (CIIE) in Shanghai.

The initial tenure of the agreement is 10 years from the first commercial sale of the said products in China, the note said, without revealing financial details. Sun’s stock price was up over 1.8 per cent at Rs 438 on the BSE, at 11.55 am on Wednesday.

According to the agreement, Sun Pharma will be responsible for development, regulatory filings and manufacturing of the products covered in the agreement while AstraZeneca will exclusively promote and distribute these products in China.

Kal Sundaram, Sun Pharma’s Director of Corporate Development, said: “We see a great potential to introduce our speciality and generics products in the growing China market and this licensing agreement is another positive step in that direction.”

CIIE is an expo organised by China’s Ministry of Commerce.

Published on November 06, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like